Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials (Q38038097)

From Wikidata

Jump to navigation Jump to search

scientific article published on 24 August 2012

Language	Label	Description	Also known as
English	Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials	scientific article published on 24 August 2012

Statements

scholarly article

1 reference

Europe PubMed Central

27 August 2017

0 references

Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials (English)

1 reference

Europe PubMed Central

27 August 2017

0 references

1 reference

based on heuristic

inferred from title

Niccolò Marchionni

8

object named as

Niccolò Marchionni

1 reference

Europe PubMed Central

27 August 2017

1

object named as

Matteo Monami

1 reference

Europe PubMed Central

27 August 2017

Edoardo Mannucci

9

object named as

Edoardo Mannucci

1 reference

Europe PubMed Central

27 August 2017

author name string

Valentina Vitale

2

1 reference

Europe PubMed Central

27 August 2017

Maria Luisa Ambrosio

3

1 reference

Europe PubMed Central

27 August 2017

Nadia Bartoli

4

1 reference

Europe PubMed Central

27 August 2017

Giulia Toffanello

5

1 reference

Europe PubMed Central

27 August 2017

Benedetta Ragghianti

6

1 reference

Europe PubMed Central

27 August 2017

Francesca Monami

7

1 reference

Europe PubMed Central

27 August 2017

language of work or name

0 references

publication date

24 August 2012

1 reference

Europe PubMed Central

27 August 2017

number of pages

11

1 reference

based on heuristic

inferred from page(s)

Advances in Therapy

1 reference

Europe PubMed Central

27 August 2017

29

1 reference

Europe PubMed Central

27 August 2017

736-746

1 reference

Europe PubMed Central

27 August 2017

9

1 reference

Europe PubMed Central

27 August 2017

https://scigraph.springernature.com/pub.10.1007/s12325-012-0045-5

0 references

Effect of a multifactorial intervention on mortality in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0045-5

21 January 2018

Cardiovascular risk factors and LDL subfraction profile in Type 2 diabetes mellitus subjects with good glycaemic control

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0045-5

21 January 2018

Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0045-5

21 January 2018

Pioglitazone and rosiglitazone: effects of treatment with a thiazolidinedione on lipids and non conventional cardiovascular risk factors.

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0045-5

21 January 2018

The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0045-5

21 January 2018

Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0045-5

21 January 2018

Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0045-5

21 January 2018

DPP-4 inhibitors and lipids: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0045-5

21 January 2018

Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0045-5

21 January 2018

The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0045-5

21 January 2018

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0045-5

21 January 2018

The effects of medications used for the management of diabetes and obesity on postprandial lipid metabolism

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0045-5

21 January 2018

Effects of pioglitazone vs glibenclamide on postprandial increases in glucose and triglyceride levels and on oxidative stress in Japanese patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0045-5

21 January 2018

Glimepiride increases high-density lipoprotein cholesterol via increasing adiponectin levels in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0045-5

21 January 2018

Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: a meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0045-5

21 January 2018

Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0045-5

21 January 2018

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0045-5

21 January 2018

Operating characteristics of a rank correlation test for publication bias

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0045-5

21 January 2018

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0045-5

21 January 2018

Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0045-5

21 January 2018

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0045-5

21 January 2018

Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group.

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0045-5

21 January 2018

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0045-5

21 January 2018

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0045-5

21 January 2018

Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, para

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0045-5

21 January 2018

Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0045-5

21 January 2018

Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study.

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0045-5

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0045-5

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0045-5

21 January 2018

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0045-5

21 January 2018

Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0045-5

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0045-5

21 January 2018

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0045-5

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0045-5

21 January 2018

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0045-5

21 January 2018

Oral antidiabetic agents in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0045-5

21 January 2018

Oral antidiabetic agents: anti-atherosclerotic properties beyond glucose lowering?

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0045-5

21 January 2018

Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load.

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0045-5

21 January 2018

National Cholesterol Education Program and International Diabetes Federation definitions of metabolic syndrome in the prediction of diabetes. Results from the FIrenze-Bagno A Ripoli study

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0045-5

21 January 2018

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0045-5

21 January 2018

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0045-5

21 January 2018

Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0045-5

21 January 2018

Identifiers

10.1007/S12325-012-0045-5

1 reference

https://api.fatcat.wiki/v0/release/pk4f5he4l5gb3kavffklsh22my

30 July 2022

based on heuristic

mapped directly with Wikidata item

Dimensions Publication ID

0 references

release_pk4f5he4l5gb3kavffklsh22my

1 reference

https://api.fatcat.wiki/v0/release/pk4f5he4l5gb3kavffklsh22my

30 July 2022

based on heuristic

mapped directly with Wikidata item

1 reference

https://api.fatcat.wiki/v0/release/pk4f5he4l5gb3kavffklsh22my

30 July 2022

based on heuristic

mapped directly with Wikidata item

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38038097&oldid=1951123495"